Table 7.
Comparison of different Studies evaluating adrenal gland endoscopic ultrasound guided fine-needle aspiration
| Ref. | Year | Number of patients | Patient population | EUS-FNA Left adrenal, n | Patient population | EUS-FNA Left adrenal, n | EUS-FNA Right adrenal, n | Benign EUS-FNA cytology, n | Malignant EUS-FNA cytology (n) | Non-Diagnostic rate | Sensitivity | Specificity | PPV | NPV | F/U for benign lesions | Method for F/U |
| Current research | 2014 | 94 | Patients undergoing EUS-FNA of either adrenal | 94 | Patients undergoing EUS-FNA of either adrenal | 90 | 5 | 60 | 25 | 10% | 86% | 97% | 96% | 89% | Available on 36/60 | CT/MRI, repeat EUS at ≥ 6 mo or surgical pathology from adrenalectomy |
| 1Uemura et al[13] | 2013 | 150 | Potentially resectable lung cancer | 150 | Potentially resectable lung cancer | 91 | 51 | 7 | 4 | 0% | 100% | 100% | 100% | 100% | Available in 4/7 | F/U CT at 6 months |
| Schuurbiers et al[17] | 2011 | 85 | Lung cancer | 150 | Lung cancer | 85 | 0 | 25 | 55 | 6% | 86% | 96% | 91% | 70% | Available in 23/30 | Clinical (n = 11) or F/U CT (n = 10)2 |
| Eloubeidi et al[12] | 2010 | 59 | Known or suspected malignancy | 59 | Known or suspected malignancy | 54 | 5 | 37 | 22 | 0% | NR | NR | NR | NR | Clinical F/U for 37 | Not part of study protocol |
| Bodtger et al[4] | 2009 | 40 | Known or suspected lung cancer | 40 | Known or suspected lung cancer | 40 | 0 | 29 | 11 | 0% | 94% | 43% | 91% | 55% | Available | Survival at 2 yr |
1
EUS-FNA was done in 11 patients, 3 had bilateral EUS-FNA;
2
Two patients had CT at 3 mo. EUS-FNA: Endoscopic ultrasound guided fine-needle aspiration; PPV: Positive predictive value; NPV: Negative predictive value; FNA: Fine-needle aspiration; F/U: Follow up; N/A: Not available; NR: Not reported; CT: Computerized Tomography.